APVOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:33):

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States...

Stats
本日の出来高	331 157
平均出来高	284 577
時価総額	504 062
EPS	$-6.16 ( 2024-04-04 )
次の収益日	( $-15.65 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00400 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Taylor Daphne	Buy	1 584	Common Stock
2024-03-02	Taylor Daphne	Buy	3 667	Common Stock
2024-03-02	Taylor Daphne	Sell	3 667	Restricted Stock Unit
2024-03-04	Taylor Daphne	Sell	1 584	Restricted Stock Unit
2024-03-03	Lamothe Jeffrey G.	Buy	3 667	Common Stock

INSIDER POWER
27.85
Last 99 transactions
Buy: 423 660 \| Sell: 158 934

Aptevo Therapeutics Inc 相関

10 最も正の相関
OPTN	0.913
VERU	0.91
QTEK	0.894
MODV	0.892
GOSS	0.891
HIBB	0.889
NVNO	0.887
TRVN	0.884
FUV	0.884
GROM	0.883

10 最も負の相関
ARNA	-0.944
MLAI	-0.914
PLPC	-0.913
FRBN	-0.912
SLAM	-0.911
VHNA	-0.911
TACT	-0.909
KAII	-0.907
BIOT	-0.907
NCAC	-0.906

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Aptevo Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-567 000 (0.00 %)
EPS:	$-62.62

FY	2023
収益:	$0
総利益:	$-567 000 (0.00 %)
EPS:	$-62.62

FY	2022
収益:	$3.11M
総利益:	$2.21M (71.07 %)
EPS:	$368.10

FY	2021
収益:	$12.29M
総利益:	$0.00 (0.00 %)
EPS:	$-6.07

Financial Reports:

No articles found.

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.